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Background. Helicobacter pylori, a bacterium that infects approximately half of the 
world’s population, is associated with various gastrointestinal diseases, including 
peptic ulcers, non-ulcer dyspepsia, gastric adenocarcinoma, and gastric lymphoma. To 
combat the increasing antibiotic resistance of H. pylori, the need for new therapeutic 
strategies has become more pressing. Characterization of the interactions between H. 
pylori and the fecal microbiome, as well as the mechanisms underlying these 
interactions, may offer new therapeutic approaches. Exploration of changes in fatty acid 
metabolism associated with H. pylori-mediated alterations of the fecal microbiome may 
also reveal strategies to help prevent progression to neoplasia. 
 
Aim. To characterize the gut microbiome and metabolome in H. pylori patients in a 
socioeconomically challenged and underprivileged inner-city community.  
 
Methods. Stool samples from 19 H. pylori patients and 16 control subjects were 
analyzed. 16S rRNA gene sequencing was performed on normalized pooled amplicons 
using the Illumina MiSeq System using a MiSeq reagent kit v2. Alpha and beta diversity 
analyses were performed in QIIME 2. Non-targeted fatty acid analysis of the samples 
was carried out using gas chromatography-mass spectrometry (GC-MS), which 
measures the total content of 30 fatty acids in stool after conversion into their 
corresponding fatty acid methyl esters. Multi-dimensional scaling (MDS) was 
performed on Bray-Curtis distance matrices created from both the metabolomics and 
microbiome datasets and a Procrustes test was performed on the metabolomics and 
microbiome MDS coordinates. 
 
Results. Fecal microbiome analysis showed that alpha diversity was lowest in H. pylori 
patients over 40 years of age compared to control subjects of similar age group. Beta 
diversity analysis of the samples revealed significant differences in microbial 
community structure between H. pylori patients and control subjects. Thirty-eight and 
six taxa had lower and higher relative abundance in H. pylori patients, respectively. 
Taxa that were enriched in H. pylori patients included Atopobium, Gemellaceae, 
Micrococcaceae, Gemellales and Rothia (R. mucilaginosa). Notably, relative abundance of 
the phylum Verrucomicrobia was decreased in H. pylori patients compared to control 
subjects, suggesting disruption of the gut mucosal environment by H. pylori. Procrustes 
analysis showed a significant relationship between the microbiome and metabolome 
datasets. Stool samples from H. pylori patients showed increases in several fatty acids 
including the polyunsaturated fatty acids (PUFAs) 22:4n6, 22:5n3, 20:3n6 and 22:2n6, 
while decreases were noted in other fatty acids including the PUFA 18:3n6. The pattern 
of changes in fatty acid concentration correlated to the Bacteroidetes:Firmicutes ratio 
determined by 16S rRNA gene analysis.  
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Conclusion. An individualized understanding of gut microbiome features among H. 
pylori patients will pave the way for improved community impact, reduced healthcare 
burdens of repeated treatment, and decreased mounting resistance. 
 




10-HOE, 10-hydroxy-cis-12-octadecenoic acid  
DHA, docosahexaenoic acid, 22:6 (n-3) 
DNL, de novo lipogenesis 
FAME, fatty acid methyl ester 
GC-MS, gas chromatography–mass spectrometry 
IBD, inflammatory bowel disease 
IRB, Institutional Review Board 
LDA, Linear Discriminant Analysis 
LEfSe, Linear Discriminant Analysis (LDA) Effect Size (LEfSe) 
MDS, multidimensional scaling 
MUFA, monounsaturated fatty acid 
OTU, operational taxonomic unit 
PCoA, principal coordinate analysis 
PERMANOVA, permutational multivariate analysis of variance 
PERMDISP, permutational analysis of multivariate dispersions 
PPI, proton pump inhibitor 
PROTEST, Procrustes randomization test 
PUFA, polyunsaturated fatty acid 
QC, quality control 
QIIME, Quantitative Insights Into Microbial Ecology 
SCFA, short-chain fatty acid      
SIM, single ion monitoring 
sOTU, sub-operational taxonomic unit 
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Helicobacter pylori, a bacterium found in the stomach of roughly half of the world’s 
population, is associated with various gastrointestinal diseases, including peptic ulcers, 
non-ulcer dyspepsia, gastric adenocarcinoma, and gastric lymphoma. Although many 
infections are asymptomatic, eradication of H. pylori has been shown to reduce the 
incidence of gastric cancer and is thus universally recommended[1]. For decades, 
clarithromycin-based triple therapy was considered the first-line therapy for H. pylori 
eradication and associated gastric cancer prevention. Following the global trend in 
emerging antibiotic resistance, rates of clarithromycin, metronidazole, and levofloxacin 
resistance among H. pylori strains have increased markedly, causing an alarmingly high 
rate of eradication failure[2]. In the absence of universally available antibiotic 
susceptibility testing, current guidelines advocate for the use of empiric quadruple 
therapy strategies; however, the efficacy of these regimens may be limited by dual 
resistance, local availability, and patient adherence[3].  
As H. pylori antibiotic resistance rises, the need for new therapeutic strategies 
becomes more pressing. Alternative antibiotics, novel acid suppressants, and 
vaccination have shown some promise in addressing this challenge[4-7]. Probiotics have 
also garnered attention for a possible role in H. pylori treatment, as infection with the 
bacterium may be associated with gastric dysbiosis, which can promote inflammation, 
metabolic disease, and carcinogenesis[8-12]. With the advent of high throughput 16S 
rRNA gene sequencing methods and open-source software for subsequent analysis and 
visualization, researchers have been able to characterize changes in the microbial 
diversity and community structure of the gut microbiota, as well as specific taxa that 
are differentially abundant in association with particular phenotypes[13]. Many studies 
have focused on H. pylori-mediated changes to the gastric microbiome, although data 
have demonstrated variable patterns of effects on multiple metrics of microbial 
diversity and community structure within the gastric microbiome[14]. Given the 
challenges associated with obtaining gastric samples, researchers have also focused on 
the impact of H. pylori infection on distal gut, i.e., fecal, microbiota, and observed 
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changes in the fecal microbiome have prompted speculation that such alterations may 
be involved in the development of gastrointestinal lesions and cancer[15]. Further 
characterization of the interactions between H. pylori and the fecal microbiome, as well 
as the mechanisms underlying these interactions, may lead to novel therapeutic 
opportunities, as well as to identification of patients at risk for progression to particular 
clinical manifestations. 
Given the association between H. pylori infection and gastrointestinal inflammation, 
attention has also been paid to compounds with anti-inflammatory activity, including 
fatty acids. Polyunsaturated fatty acid (PUFA) supplementation in particular may have 
therapeutic potential for H. pylori treatment via multiple mechanisms, including 
suppression of inflammatory cytokines and enzymes and direct bacteriocidal effects via 
disruption of cell membranes[16-18]. 10-hydroxy-cis-12-octadecenoic acid (10-HOE; a 
linoleic acid derivative) and docosahexaenoic acid (DHA) have both been shown to 
inhibit in vitro growth of H. pylori and gastric infection in mouse models[19, 20]. 
Nevertheless, the effects of H. pylori infection on fatty acid metabolism in the 
gastrointestinal tract are not completely understood. Furthermore, the extent to which 
such metabolomic changes may relate to alterations in the gastrointestinal microbiota 
are unknown. Notably, short-chain fatty acids (SCFAs) produced by gut microbiota are 
thought to play a role in intestinal homeostasis and regulation of immune function, and 
dysbiosis in the setting of inflammatory bowel disease (IBD), which is associated with 
decreased levels of these important molecules[21, 22]. Exploration of changes in fatty acid 
production and metabolism associated with H. pylori-mediated alterations of the fecal 
microbiome is warranted, as it may reveal strategies to inhibit the cascade of events 
leading to neoplasia. 
Previously, we studied the pattern of H. pylori prevalence and antibiotic resistance in 
our socioeconomically challenged and underprivileged inner-city community[23]. As a 
next step, we then sought to characterize the gut microbiome associated with H. pylori 
infection in our patients. We further explored interactions among H. pylori infection, the 
gut microbiota, and the gut metabolome by comparing stool fatty acid profiles between 
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subjects with and without H. pylori infection. Our overarching goal is to identify 
potential targets for intervention that could improve H. pylori eradication rates and limit 
the consequences of repeated treatment failure. 
 
MATERIALS AND METHODS 
Patients and sample collection 
Patients presenting to the Cooper Digestive Health Institute in Camden, New Jersey 
and diagnosed with H. pylori infection via biopsy were recruited for our study. H. pylori 
patients at least 18 years of age and diagnosed via biopsy between June 1, 2017 and 
December 31st, 2019, were eligible for inclusion. Patients less than 18 years old, 
pregnant women, patients taking antibiotics at the time of recruitment or sampling, and 
non-English speaking patients were excluded from participation. Control participants 
were recruited from a healthy population, also seen at Cooper Health Institute for well 
visits. Informed consent was obtained by one of several IRB-approved team members. 
Surveys about demographic information and relevant medical history were collected. 
Information on diagnosis, disease features, medication, history of antibiotic use, and 
treatment regimen were collected from the electronic medical record. Patients were 
asked to provide a stool sample before initiating eradication therapy, and samples were 
collected and stored in Stool Nucleic Acid Collection and Preservation Tubes (Cat. No. 
45630, 45660, Norgen Biotek Corp., Thorold, Ontario, Canada) prior to freezing at –80 
oC as described previously[23]. 
16S rRNA gene sequencing 
Total genomic bacterial DNA extraction was performed from frozen fecal samples using 
the Qiagen DNeasy PowerSoil HTP Kit (Cat. No. 12955-4, Qiagen, Valencia, CA, USA). 
Adequate DNA yield was confirmed using NanoDrop spectrophotometry. For high 
throughput sequencing, 515F–806R Golay barcodes were used to target the 
hypervariable V4 region of the 16S rRNA gene, which is highly conserved and ideal for 
gut microbiome analysis. Marker genes in isolated DNA were PCR-amplified using 
GoTaq Master Mix (Cat. No. M5133, Promega, Madison, WI, USA) as described in 
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Caporaso et al.[24] PCR products were cleaned and normalized using the SequalPrepTM 
Normalization Plate Kit (Cat. No. A1051001, ThermoFisher, Waltham, MA, USA) 
following manufacturer’s instructions. Purification of PCR product amplicons was 
performed with the QIAquick PCR Purification Kit (Cat. No. 28104, Qiagen). 
Quantification of the PCR amplified library was performed with the InvitrogenTM 
Quant-iTTM PicoGreenTM dsDNA Assay Kit (Cat. No. P7589, ThermoFisher). 16S rRNA 
gene sequencing was performed on normalized pooled amplicons using the Illumina 
MiSeq System using a MiSeq reagent kit v2 (300 cycles; Cat. No. MS-102-2002, Illumina 
Inc.). FASTQ files for reads 1 (forward), 2 (reverse), and the index (barcode) read were 
generated using the BCL-to-FASTQ file converter bcl2fastq (ver. 2.17.1.14, Illumina, 
Inc.). Sequencing of the samples was conducted at the University of Colorado Boulder 
BioFrontiers Next-Gen Sequencing core facility.   
Sequencing data analysis 
Analysis was performed using Python-based packages (Python 3.6.12), QIIME 2 2019.4 
(denoising and taxonomy assignment), Quantitative Insights Into Microbial Ecology 
(QIIME) 2 2020.11 (statistical testing), and Linear Discriminant Analysis using 
LEfSe10[25, 26]. Sequences were de-multiplexed then filtered and clustered into sub-
operational taxonomic units (sOTUs) using QIIME 2  DADA2[27]. A masked 
phylogenetic tree was created using MAFFT via QIIME2[28, 29]. Taxonomy was assigned 
using a naïve-Bayes classifier based on the latest Greengenes 16S rRNA gene database 
available as of August 2019 via the QIIME 2 interface (gg_13_8). Additional Python 
packages (SciPy.stats, Scikit-bio) were used for statistical tests on QIIME 2-generated 
data. Inter-class comparisons were made based on attributes of our population 
including: H. pylori status, gender, age group, race, education, and alcohol use. Alpha 
and beta diversity analyses were performed in QIIME 2, rarefied to an even sampling 
depth of 22,400[30]. Alpha diversity was assessed by Faith’s phylogenetic diversity, 
chao1 index, and observed operational taxonomic units (OTUs). Differences in alpha 
diversity between groups were determined by Kruskal-Wallis non-parametric rank test 
for categorical variables or by Fisher Z transformation on Spearman rho values for 
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differences between alpha diversity correlations with numeric data across groups. 
Bacterial composition (beta diversity) was analyzed by principal coordinate analyses 
(PCoA) of both unweighted and weighted unique fraction metric (UniFrac) 
phylogenetic distance matrices[31-34]. Beta diversity was assessed for statistical 
significance between groups using Monte Carlo permutations [Adonis and 
permutational multivariate analysis of variance (PERMANOVA)], and dispersion of 
group samples was assessed using permutational analysis of multivariate dispersions 
(PERMDISP)[35, 36]. Comparisons of relative abundances of microbial taxa between 
groups were performed using Linear Discriminant Analysis (LDA) Effect Size (LEfSe) 
with the Huttenhower et al. online interface[37]. Taxa with an LDA value of 2.0 or greater 
and a two-tailed p value ≤ 0.05 with Kruskal-Wallis and pairwise Wilcoxon analyses 
were considered significantly enriched. The code is available 
at https://github.com/sterrettJD/H-pylori-microbiome-analysis.  
Non-targeted fatty acid analysis  
Collected fecal samples were stored at –80 oC until analysis. Sample preparation and 
analysis were performed using gas chromatography–mass spectrometry (GC-MS) by 
Metabolon, Inc. (Durham, NC, USA). This method (Metabolon TAM112-002) measures 
the total content of 30 fatty acids in stool samples after conversion into their 
corresponding fatty acid methyl esters (FAMEs). The measured concentrations are 
provided in weight corrected μg/g of sample. NQ values were treated as a 
concentration of 0.001g/mL. 
Briefly, stool samples were homogenized and the suspension was weighed out in a 
100 mg aliquot in a test tube. Liquid/liquid extraction was performed to extract fatty 
acids and remove the nucleic acid preservative. A 250 μL aliquot of each extract was 
transferred to a clean analysis tube. The solvent was removed by evaporation under a 
stream of nitrogen. Internal standard solution was added to the dried sample extracts, 
quality controls (QCs), and calibration standards. The solvent was again removed by 
evaporation under a stream of nitrogen. The dried samples and QCs were subjected to 
methylation/transmethylation with methanol/sulfuric acid, resulting in the formation 
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of the corresponding methyl esters (FAME) of free fatty acids and conjugated fatty 
acids. The reaction mixture was neutralized and extracted with hexanes. An aliquot of 
the hexanes layer was injected onto a 7890A/5975C GC/MS system (Agilent 
Technologies, Santa Clara, CA, USA). Mass spectrometric analysis was performed in the 
single ion monitoring (SIM) positive mode with electron ionization. Quantitation was 
performed using both linear and quadratic regression analysis generated from fortified 
calibration standards prepared immediately prior to each run. Raw data were collected 
and processed using Agilent MassHunter GC/MS Acquisition B.07.04.2260 and Agilent 
MassHunter Workstation Software Quantitative Analysis for GC/MS B.09.00/ Build 
9.0.647.0. Data reduction was performed using Microsoft Office 365 ProPlus Excel. The 
metabolomic data set for 19 test and 12 control samples is included in the 
Supplementary materials (Full data set H. pylori). Volcano plot data are also included as 
Supplementary Tables S1, S2 and S3 (Table S1: Volcano plot data with all Helicobacter 
data set, Table S2: Volcano plot data with High Bacteroidetes and Table S3: Volcano plot 
data with High Firmicutes).  
Procrustes analysis  
Multi-dimensional scaling (MDS, using the Python package Scikit-learn) was performed 
on Bray-Curtis distance matrices created from both the fecal metabolome and fecal 
microbiome datasets (using the Python package SciPy.distance), and a Procrustes test 
was performed on the metabolomics and microbiome MDS coordinates. As described 
by Peres-Neto and Jackson, a Procrustes randomization test (PROTEST) was performed 
by randomly sampling the MDS coordinates and performing a Procrustes test on the 
reordered coordinates 10,000 times, and the p value was calculated based on the portion 
of randomized Procrustes tests with resulting m2 (Gower’s statistic) scores lower than 
the Procrustes m2 score of the observed datasets[38]. 
Ethics approval 
This study received approval by the Cooper Health System Institutional Review Board 
(IRB) (17-077EX) and all the steps were carried out as per the standards set by the IRB. 
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Fecal microbiome analysis 
Selected demographic attributes of our participants are presented in Table 1. Fecal 
microbiome analysis of 35 stool samples collected from 19 H. pylori patients and 16 
healthy control subjects was carried out. The mean number of reads per sample was 
269,462 with a minimum of 22,483 reads/sample. Rarefaction was set to 22,400 for even 
sampling based on this minimum.  We analyzed the effect of each of the factors 
included in Table 1 on alpha and beta diversity. Age was the only factor that showed 
statically significant differences (p value of ≤ 0.05) in the H. pylori patients compared to 
the control subjects.  
Analysis of alpha diversity 
Chao1 index alpha diversity between H. pylori patients and control subjects and 
regression analysis of observed OTUs by age are shown in Figure 1. Alpha diversity, 
which estimates the diversity of a microbial community within a sample, incorporates 
the number of different OTUs and their respective abundance in each sample. Alpha 
diversity was lowest in H. pylori patients over 40 years of age, who had significantly 
lower Chao1 scores compared to control subjects over 40 years of age (Kruskal-Wallis H 
= 6.036, p = 0.014). H. pylori patients over 40 years old also had lower Chao1 scores 
approaching statistical significance when compared to H. pylori patients under 40 
(Kruskal-Wallis H = 2.813, p = 0.094). Additionally, the correlation of age with observed 
OTUs (Figure 1B), Faith's phylogenetic diversity, and Chao1 was consistently different 
between H. pylori patients versus control subjects, as evidenced by a Fisher Z 
transformation on Spearman rank correlation rho values (observed OTUs: H. pylori rho = 
–0.21 vs control rho = 0.50, Fisher p = 0.041; Faith: H. pylori rho = –0.04 vs control rho = 
0.57, Fisher p = 0.067; Chao1: H. pylori rho = –0.15 vs control rho = 0.44, Fisher p = 0.097).  
Next we analyzed beta diversity of our samples, which estimates how samples differ 
from each other. An unweighted UniFrac PCoA plot of H. pylori patients versus control 
subjects is shown in Figure 2. Adonis testing revealed that current H. pylori infection 
represented 7% of the variation in unweighted UniFrac beta diversity (F = 2.523, R2 = 
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0.071, p = 0.002). Additionally, unweighted UniFrac PERMANOVAs identified 
significant differences between H. pylori patients and control subjects (F = 2.523, p = 
0.001). Furthermore, unweighted UniFrac PERMDISP did not reveal differences in 
dispersion among H. pylori patients versus control subjects (F = 0.0506, p = 0.809), but 
weighted UniFrac PERMDISP did (F = 6.82955, p = 0.017). We also explored the effect of 
the use of proton pump inhibitors (PPIs) via beta diversity analysis as PPIs are the 
medications commonly given to H. pylori patients and we had previously noted their 
influence on the antibiotic resistance of H. pylori[23]. Unweighted UniFrac 
PERMANOVA identified differences between PPI users and non-users across all 
participants (F = 1.939, p = 0.012), though the magnitude of the effect was smaller than 
that seen for H. pylori infection as described above. It should also be noted that only 
four H. pylori patients and one control subject were on PPI at the time of study and 
sample collection, so its contribution to the results described here may not be 
significant.  
Linear discriminant analysis effect size 
LEfSe scores for taxa that were differentially distributed across H. pylori patients versus 
control subjects are shown in Figure 3. Thirty-eight taxa had lower relative abundance 
in H. pylori patients relative to healthy control subjects, and six taxa had higher relative 
abundance in H. pylori patients relative to healthy control subjects. Taxa that were 
enriched in H. pylori patients include Atopobium, Gemellaceae, Micrococcaceae, 
Gemellales and Rothia (R. mucilaginosa). Figure 4 shows the arcsin square root 
transformed relative abundances of each phylum, grouped by H. pylori status. Notably, 
relative abundance of the phylum Verrucomicrobia was decreased in H. pylori patients 
compared to control subjects. 
Procrustes analysis 
The Procrustes randomization test was carried out to investigate the relationship 
between the fecal microbiome and fecal metabolome. Procrustes analysis identified a 
significant relationship between the two datasets, as the resulting p-value of 0.017 
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indicates that the correspondence of each participant's fecal microbiome to their fecal 
metabolome was better than 98% of randomly sampled simulations (Figure 5). 
Fecal Fatty acid analysis  
To evaluate the impact of H. pylori infection on fatty acid composition, we performed 
non-targeted metabolomics analysis of a panel of 30 fatty acids including long chain 
fatty acids (LCFAs), monounsaturated fatty acids (MUFAs) and polyunsaturated fatty 
acids (PUFAs). We prepared a volcano plot evaluating changes in fatty acid profile for 
the entire population of H. pylori patient samples relative to healthy control subjects 
(Figure 6a). In addition, we prepared separate volcano plots for subgroups of the H. 
pylori patients with high Bacteroidetes and high Firmicutes based on 16S rRNA gene 
analysis (Figure 6b and c). See Supplementary materials (Tables S1, S2, S3) for the full 
volcano plot data. Volcano plots allow for the plotting of p-values versus fatty acid fold 
change from control samples for all evaluated fatty acids.     
Stool samples from H. pylori patients showed increases in several fatty acids including 
the PUFAs 22:4n6, 22:5n3, 20:3n6 and 22:2n6 while decreases were noted in fatty acids 
including the PUFA 18:3n6, relative to healthy control subjects. The pattern of changes 
in fatty acid concentration was correlated to the Bacteroidetes:Firmicutes ratio 
(determined by 16S rRNA gene analysis). Among the sub-population identified to have 
high Bacteroidetes (Bacteroidetes:Firmicutes ratio ≥ 1 standard deviation above control 
ratio, n=7) we found several fatty acids that were diminished from control including the 
LCFAs 24:0, 22:0 and 15:0 along with MUFAs 20:1n9 and 18:1n9. By contrast, in the sub-
population identified to have high Firmicutes (Firmicutes:Bacteroidetes ratio ≥ 1 
standard deviation above control ratio; n=4) a distinct set of fatty acids were found to be 
significantly increased and decreased from controls. In this subpopulation we observed 
increases in the PUFA 22:2n6 and decreases in PUFAs 18:3n6 and 20:4n3.   
DISCUSSION 
Our sample size is modest due to the stringent limitations posed by the socioeconomic 
and cultural attributes of our patient population and logistic challenges. Camden 
County has the lowest median income and highest poverty and unemployment rates in 
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southern New Jersey. It also has the lowest educational attainment and the greatest 
socioeconomic disparities among ethnic minority groups. More than one third of the 
population in Camden City, where our hospital is located, lives below the national 
poverty line, and the median household income is USD $26,105[39]. Our local community 
is thus considered one of the poorest and most economically distressed communities in 
the United States. A significant fraction of adults over 25 years old (almost one quarter) 
have not completed high school. It is possible that this influences patients’ appreciation 
of the relevance of the study and willingness to participate. Please note that in the 
present study, 13 out of 19 participating patients had education level of high school or 
less. A significant portion of potential participants were excluded due to non-English-
speaking status, thus being unable to partake in the informed consent process. Logistic 
challenges imposed by the process of stool sample collection also limited the number of 
subjects. A large number of potential participants were unable to return to the clinic for 
stool sample delivery due to poor transportation access or inability to leave 
employment or domestic responsibilities during the window for sample collection (after 
diagnosis but prior to initiation of antibiotics). Nonetheless, the present study yielded 
meaningful results. 
H. pylori infection was associated with significantly decreased fecal microbial 
diversity among patients over the age of 40 years, while the control subjects had the 
highest microbial diversity. Correlations between age and multiple metrics of microbial 
alpha diversity were consistently different between H. pylori patients and control 
subjects. H. pylori was also shown to account for a significant portion of the variation in 
beta diversity between infected patients and control subjects. Collectively, these results 
could suggest an H. pylori-mediated transformation of the fecal microbiome that 
progresses with age and becomes apparent by mid-adulthood. Central to this 
transformation is a decline in fecal microbial diversity that may be the result of long-
standing infection in which H. pylori alters the gastrointestinal environment at the 
expense of other taxa. This conclusion is consistent with those of other studies that 
attributed decreased diversity of gastric microbiota to the ability of H. pylori to 
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outcompete other species[9, 14, 40]. Secretion of antibacterial peptides and local pH 
alterations have been proposed as mechanisms that may account for the alteration of 
the gastric microbiota diversity and community structure by H. pylori[41]. The impact of 
H. pylori on fecal microbial diversity observed in our study may be reversible, just as a 
recent study showed that H. pylori eradication could restore gastric microbial diversity 
to levels seen in uninfected controls[42]. 
Conversely, the data may reflect a preceding decrease in gut microbial diversity that 
facilitates H. pylori infection, possibly mediated by other factors or exposures that 
accumulate with age. In other words, patients who experience decreased gut microbial 
diversity as they age, potentially mediated by diet or chronic inflammation, may be 
more prone to H. pylori infection, particularly by mid-adulthood. In our previous study 
of 2,014 H pylori patients, we observed that 80% of our patients were above the age of 40 
years[23]. Antibiotic exposure is known to alter the gut microbiome, and increased rates 
of antibiotic resistant-H. pylori among older adults have been attributed to increased 
antibiotic use compared to younger patients[2, 43, 44]. Conceivably, decreased gut 
microbial diversity induced by cumulative antibiotic exposure could create an 
intragastric niche for H. pylori, and antibiotic resistant H. pylori strains in particular, to 
thrive.   
LEfSe showed that multiple taxa were differentially enriched or depleted in stool 
from H. pylori patients compared to controls. The significance of differential expression 
of these taxa is unknown; however, certain taxa stand out. The enrichment of Atopobium 
is notable in the context of a metagenomic analysis which revealed increased Atopobium 
parvulum abundance among patients with colorectal intramucosal carcinomas[45]. 
Although H. pylori is predominantly associated with gastric cancers, a recent meta-
analysis suggested a significantly increased risk of colorectal cancer as well, and our 
data suggest that H. pylori-associated increases in Atopobium abundance may have a role 
in the distal gut carcinogenesis[46].   
Over-representation of Rothia mucilaginosa, a commensal oral microbe, has 
previously been observed in fecal samples from patients with primary sclerosing 
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cholangitis (PSC)[47]. Because of the sensitivity of R. mucilaginosa to gastric fluid, Bajer et 
al. hypothesized that its presence in PSC patients represented contamination of the 
intestine via previous endoscopic retrograde cholangiopancreatography[47]. The 
enrichment of Rothia sp. in fecal samples from our H. pylori patients may reflect the 
potent gastric acid suppression by H. pylori, allowing translocation of swallowed oral 
flora to the distal gut. The clinical consequences of the colonization of the distal gut by 
Rothia sp. are unknown, although the bacteria has been implicated as a cause of myriad 
syndromes, including dental caries, pneumonia, and bacteremia, particularly in 
immunocompromised patients[48]. The increased abundance of Gemellaceae in H. pylori 
patients is consistent with the observation of increased organisms from the Gemella 
genus in patients with current H. pylori infection reported by Gao et al[49]. Microbial 
shift that included the expansion of Gemellaceae in the Crohn ileum has been reported 
by other groups[50, 51].   
Interestingly, the phylum Verrucomicrobia was significantly depleted in H. pylori 
patients. Verrucomicrobia includes Akkermansia muciniphila, a mucus-residing 
commensal bacterium of the large intestine. A. muciniphila is an obligate 
chemoorganotroph, utilizing mucus as a sole carbon, nitrogen, and energy source that 
produces SCFAs including acetate, propionate, and, to a smaller extent, 1,2-
propanediol[52, 53]. Decreased relative abundance of Verrucomicrobia may suggest 
disruption of the gut mucosal environment by H. pylori. In a mouse stress model, 
exposure to chronic psychosocial stress resulted in expansion of Helicobacter spp., which 
has been demonstrated to proliferate in response to glucocorticoid administration as 
well as psychosocial stress exposure[54]. Specifically, stress-induced increases in 
Helicobacter spp. were associated with increases in other Proteobacteria spp., including 
unidentified genera belonging to the Enterobacteraceae and Desulfovibrionaceae 
families. Concurrently, relative abundance of Mucispirillum, an obligate mucus-residing 
bacterium, decreased; a decline of Mucispirillum in rodents is associated with early 
disruption of the gastrointestinal surface mucus layer and a prolonged delay to 
recovery after the period of pathogen clearance[55]. Evidence of disruption of the gut 
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mucosa by H. pylori infection is also consistent with decreased relative abundance of 
Faecalibacterium prausnitzii. F. prausnitzii is an important gram-positive human 
commensal that produces butyrate and other SCFA through the fermentation of dietary 
fiber. Reduced relative abundance of F. prausnitzii has been associated with 
inflammatory conditions including Crohn’s disease, obesity, asthma, and stress-related 
psychiatric disorders in which inflammation is a risk factor, such as major depressive 
disorder[56-59]. 
The gastric microbiome differs significantly from those of other sites along the 
gastrointestinal tract[60]. Nevertheless, H. pylori infection is thought to indirectly alter 
distal gut microbial community structure[61]. Recent studies have identified significant 
differences in bacterial communities obtained from human duodenal and stool samples 
associated with H. pylori infection [62, 63]. Schulz et al. identified a few phylotypes that 
were detected at significantly different rates in duodenal aspirates or biopsies of H. 
pylori-positive individuals compared to controls, and this finding may be related to H. 
pylori’s association with duodenal ulcers[62]. In contrast to our study, Dash et al. 
observed increased alpha diversity among stool samples from H. pylori-positive 
individuals, although they found no effect on beta diversity[63]. Finally, Frost et al. found 
significant changes in fecal microbiome diversity and composition as measured by 
alpha and beta diversity, respectively, in H. pylori positive individuals compared to 
controls, and the latter association was strongly correlated with H. pylori stool antigen 
load[64]. Differences in the study populations, including geographic, cultural, and 
dietary differences, may account for these conflicting findings regarding H. pylori’s 
effects on the distal gut microbiome, as these factors are known to significantly impact 
fecal microbiome composition[65]. Moreover, methodological differences in analyses of 
alpha and beta diversity and relative taxonomic abundance further inhibit comparison 
of study results. Nevertheless, our results add to the growing evidence suggesting that 
H. pylori is associated with alterations in distal gut microbiota, particularly in those over 
40 years of age.  
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Strategies to promote increased gut microbial diversity among patients with H. 
pylori infection, particularly those over 40 years of age, may hold therapeutic potential 
in eradicating infection, and some clinical trials with adjunctive probiotic formulas have 
shown promising results in this regard[66]. Likewise, treatment of gut dysbiosis in 
patients with H. pylori infection may limit its associated pathologies. Reduced fecal 
microbiome diversity is associated with multiple disease markers including increased 
adiposity, insulin resistance, dyslipidemia, and a pro-inflammatory state [67]. H. pylori 
infection is associated with higher rates of diabetes, specifically, and addressing gut 
dysbiosis in such patients could conceivably aid primary dietary and pharmacologic 
strategies to achieve glycemic control and insulin sensitivity[12]. Rehabilitation of the gut 
microbiota in patients with H. pylori may also have a role in minimizing the risk of 
malignancy. Mouse studies suggest that the carcinogenic effects of H. pylori partly 
depend on interactions with the gut microbiome, and persistent infection with H. pylori 
may create a niche favorable for taxa that are found in increased abundance in gastric 
cancer, including Lactobacillus and Lachnospiraceae[9, 68, 69]. It has been suggested that 
lactic acid bacteria can influence gastric cancer by a number of mechanisms such as (i) 
supply of exogenous lactate, that acts as a fuel source for cancer cells, (ii) production of 
reactive oxygen species and N-nitroso compounds and (iii) by allowing colonization of 
carcinogenic non-H. pylori bacteria[70]. Accordingly, reversal of abnormalities in gut 
microbiota associated with H. pylori may also limit its carcinogenic potential. Finally, 
consideration must be given to the effects of H. pylori treatment on the gut microbiome, 
as data suggest that current therapies may be associated with dysbiosis and subsequent 
adverse effects[71]. 
While evaluating changes in the long-chain fatty acids (LCFAs) palmitic (16:0) and 
stearic (18:0) concentrations, we found that palmitic acid concentrations were increased 
in our test samples compared to control samples (625.23 598.82 g/g (n=18) versus 
334.10 284.58 g/g (n=12)), whereas concentrations of stearic acid were comparable 
between populations. Interestingly, when we evaluated the high Firmicutes (>1.4:1 
Firmicutes: Bacteroidetes, n=4) sub-group compared to the high Bacteroidetes (>2.7:1 
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Bacteroidetes: Firmicutes, n=7) sub-group of our test population we found the 
concentrations of both these LCFAs to be diminished in the high Bacteroidetes 
population while the concentrations of both were enhanced in the high Firmicutes sub-
population. This is consistent with previous studies in mice where administration of 
LCFA-rich diets resulted in an observed increase in Firmicutes to Bacteroidetes ratio[72]. 
Ktsoyan et al. implicated a characteristic profile of serum LCFA concentrations in 
association with H. pylori infection compared to healthy controls[73]. It is plausible that 
diet can modulate the impact of H. pylori on the gut microbiome, which in turn may 
relate to different disease phenotypes, i.e., asymptomatic infection, peptic ulcer disease, 
and gastric cancer. 
The accumulation of the saturated LCFAs is regulated under normal physiological 
conditions by desaturation of 16:0 to 16:1n7, elongation of 16:0 to 18:0 and/or 
desaturation of 18:0 to 18:1n9 which can be further elongated to 20:1n9 (Figure 7). While 
only small changes in concentrations of these MUFAs were noted between our H. pylori 
patients and control subjects, the changes in MUFA concentrations in our high 
Firmicutes and high Bacteroidetes sub-populations showed more significant and 
consistent changes across the series of MUFAs. The concentration of 16:1n7, 18:1n9 and 
20:1n9 were decreased in the high Bacteroidetes sub-group, whereas these MUFAs were 
slightly increased in the high Firmicutes sub-group. Interestingly, this contrasts 
published data on the benefits of high MUFA diets in animal models and humans. In 
previous studies, high MUFA diets have been reported to lead to increased ratios of 
Bacteroidetes to Firmicutes and were correlated with reductions in several disease 
indicators[72]. Together, these observations may suggest that either the patients in our 
high Bacteroidetes sub-population have severely limited MUFA production/intake, 
contrasting previous work on MUFA rich diets or that the endogenous biosynthetic 
pathways for MUFA production are dysregulated in this patient population.  
The range of PUFAs observed endogenously have essential physiological roles and 
are produced from dietary alpha-linolenic acid (18:3n3) and linoleic acid (18:2n6). We 
observed that both of these dietary PUFAs were increased in our test samples compared 
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to the control samples. In humans, C18:2n6 is converted through multiple steps to 
eicosapentaenoic acid (EPA, 20:5n3) and docosahexaenoic acid (DHA, 22:6n3), whereas 
18:3n3 proceeds to produce arachidonic acid (AA, 20:4n6) (Figure 7). As these two 
biosynthetic pathways share enzymes for their respective dehydration and elongation 
steps, they are antagonistic to each other. In general, a high 18:3n3 (n-3 fatty acid) diet is 
correlated with positive physiological effects whereas a high 18:2n6 (n-6 fatty acid) diet 
is correlated with metabolic dysbiosis and negative physiological effects[74, 75]. 
Accordingly a balanced dietary intake of n-6/n-3 fatty acids is recommended to be 1:1-
2:1, although the average ratio in a typical Western diet has been reported to be >15:1[76]. 
In accordance with published ratios for n-6/n-3 fatty acid intake in Western diets, we 
find the ratio of 18:2n6/18:3n3 to be 22:1 in our control samples and 15:1 in our H. pylori 
patient test samples.  
Endogenously, the essential dietary fatty acid 18:3n3 undergoes multiple 
dehydration and elongation steps to produce docosapentaenoic acid (DPA, 22:5n3) and 
docosahexaenoic acid (DHA, 22:6n3). For all intermediates along this biosynthetic 
pathway, with exception to 18:3n3 and 22:5n3, we observe concentrations at or below 
the limit of quantification for the majority of samples making an evaluation of the 
individual steps of this biosynthesis pathway difficult.  
Contrasting the low concentrations observed for 18:3n3 and fatty acids produced 
along this biosynthetic pathway, higher overall concentrations were observed for fatty 
acids derived from 18:2n6, perhaps reflecting the higher concentration of dietary n-6 
fatty acids as described earlier. In humans, the dietary fatty acid, 18:2n6 undergoes 
dehydration to produce 18:3n6. This intermediate undergoes a subsequent elongation to 
produce 20:3n6, which is dehydrated to 20:4n6 (arachidonic acid). Alternatively, 18:2n6 
can undergo elongation first to produce 20:2n6, which is dehydrated to produce 20:3n6 
(Figure 7).  
We found that the early steps in the metabolism of 18:2n6 were significantly 
impacted in all of our H. pylori samples by comparison of downstream fatty acid 
metabolites to controls. Most notably, in all H. pylori test samples the concentration of 
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18:3n6 was significantly diminished. Concentration of 18:3n6 was 10.7 18.2 g/g (n=12) 
in the control samples and 0.36 1.50 g/g (n=18) in the test samples. While we would 
anticipate that this deficiency in dehydration of 18:2n6 would lead to lower levels of 
fatty acid metabolites downstream of 18:3n6, this is not the case. In fact, by the 
following biosynthetic step, i.e., elongation to produce 20:3n6, the fatty acid 
concentration of 20:3n6 in test samples was found to be higher than in controls. These 
higher concentrations were also reflected in arachidonic acid (20:4n6) and adrenic acid 
(22:4n6). It is plausible that the alternative -8-desaturase mediated route via 20:2n6 may 
be prominent in these H. pylori patient samples, which are marked by a deficiency in -
6-desaturase mediated pathway via 18:3n6[77]. 
As the burden of antibiotic resistance grows, populations like ours are impacted 
greatly by the high prevalence of H. pylori colonization. As eradication by a one-fits-all 
approach becomes more and more difficult, it becomes even more important to look 
towards strategies that can provide insight into community attributes that can help 
guide targeted therapies, predict likelihood of treatment outcomes, and possibly create 
strategies towards mitigating the impact of increased antibiotic usage. A greater, more 
individualized understanding of gut microbiome features among patients experiencing 
H. pylori colonization, especially in our underserved population, will pave the way for 
better community impact and reduce healthcare burdens of repeated treatment and 
mounting resistance. As gut dysbiosis is inextricably tied not only to H. pylori infection 
but also to the use of antibiotics itself, the cycle of treatment and re-treatment may very 
well only further exacerbate vulnerability to enteric pathogens. Strategies to better 
understand gut dysbiosis features among affected groups may create opportunities for 
targeted therapy, as well as a potential for creating predictive models for antibiotic 
selection, and even exploring restorative probiotic therapy to help lessen the adverse 
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Table 1. Patient Demographics and Clinical Characteristics 
 Total (n = 35) H. pylori patients (n = 19) Control (n = 16) 
Sex    
Male 19 (54%) 13 (68%) 6 (38%) 
Female 16 (46%) 6 (32%) 10 (62%) 
Age    
Ages 18-40 15 (43%) 3 (16%) 12 (75%) 
Age >40 20 (57%) 16 (84%) 4 (25%) 
Highest education    
Less than 
high school 
2 (6%) 2 (11%) 0 (0%) 
High school 12 (34%) 11 (58%) 1 (6%) 
Undergradu
ate 
4 (11%) 2 (11%) 2 (13%) 
Graduate 15 (43%) 3 (16%) 12 (75%) 
Post-
graduate 
1 (3%) 0 (0%) 1 (6%) 
Race    
African 
American 




2 (6%) 0 (0%) 2 (12%) 
Caucasian 13 (37%) 1 (5%) 12 (75%) 
Non-White 
Hispanic 
8 (23%) 8 (42%) 0 (0%) 
Other 3 (9%) 3 (16%) 0 (0%) 
Smoker 5 (14%) 4 (21%) 1 (6%) 
Past H. pylori 
treatment 
1 (3%) 1 (5%) 0 (0%) 
Duodenal ulcer 1 (3%) 1 (5%) 0 (0%) 
Non-ulcer 
dyspepsia 
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Figure 7. Major metabolic pathways. Selected long-chain fatty acids (LCFAs, no fill), 
monounsaturated fatty acids (MUFAs, light grey fill) and polyunsaturated fatty acids 
(PUFAs, dark grey fill) are highlighted. Although many of the fatty acids shown may be 
supplemented by diet, key parent members of these pathways acquired from de novo 
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